$3995 | Single User
$7990 | Site License
$11985 | Enterprise License

Diabetes & Obesity Drug Development Pipeline Review, 2016

Published by GBI Research: 01 Dec 2016 | 25791 | In Stock

Introduction

Diabetes & Obesity Drug Development Pipeline Review, 2016

Summary

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.

Scope

- Which companies are the most active within the pipeline for diabetes and obesity?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?

- What are the most important R&D milestones and data publications to have occurred in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Table of Contents
for Diabetes & Obesity Drug Development Pipeline Review, 2016

  • Table of Contents

    Table of Contents 4

    List of Tables 6

    List of Figures 22

    Diabetes and Obesity Report Coverage 24

    Type 1 Diabetes (Juvenile Diabetes) Overview 24

    Type 2 Diabetes Overview 24

    Obesity Overview 24

    Therapeutics Development by Stage 25

    Type 1 diabetes (Juvenile Diabetes) 25

    Type 2 Diabetes 27

    Obesity 29

    Therapeutics under Development by Companies 31

    Type 1 Diabetes (Juvenile Diabetes) 31

    Type 2 Diabetes 41

    Obesity 61

    Therapeutics under Investigation by Universities/Institutes 70

    Type 1 diabetes (Juvenile Diabetes) 70

    Type 2 Diabetes 72

    Obesity 75

    Pipeline Products Glance 78

    Type 1 diabetes (Juvenile Diabetes) 78

    Type 2 Diabetes 81

    Obesity 84

    Products under Development by Companies 87

    Type 1 diabetes (Juvenile Diabetes) 87

    Type 2 Diabetes 98

    Obesity 121

    Products under Investigation by Universities/Institutes 130

    Type 1 diabetes (Juvenile Diabetes) 130

    Type 2 Diabetes 133

    Obesity 139

    Companies Involved in Therapeutics Development 143

    Type 1 diabetes (Juvenile Diabetes) 143

    Type 2 Diabetes 196

    Obesity 309

    Therapeutics Assessment 361

    Type 1 diabetes (Juvenile Diabetes) 361

    Type 2 Diabetes 387

    Obesity 440

    Dormant Projects 462

    Type 1 diabetes (Juvenile Diabetes) 462

    Type 2 Diabetes 471

    Obesity 495

    Discontinued Products 509

    Type 1 diabetes (Juvenile Diabetes) 509

    Type 2 Diabetes 512

    Obesity 521

    Product Development Milestones 525

    Type 1 diabetes (Juvenile Diabetes) 525

    Type 2 Diabetes 537

    Obesity 549

    Appendix 559

    Methodology 559

    Coverage 559

    Secondary Research 559

    Primary Research 559

    Expert Panel Validation 559

    Contact Us 559

    Disclaimer 560

List Of Tables
in Diabetes & Obesity Drug Development Pipeline Review, 2016

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 25

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 26

Number of Products under Development for Type 2 Diabetes, H2 2016 27

Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 28

Number of Products under Development for Obesity, H2 2016 29

Number of Products under Development for Obesity – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 32

Number of Products under Development by Companies, H2 2016 (Contd..1) 33

Number of Products under Development by Companies, H2 2016 (Contd..2) 34

Number of Products under Development by Companies, H2 2016 (Contd..3) 35

Number of Products under Development by Companies, H2 2016 (Contd..4) 36

Number of Products under Development by Companies, H2 2016 (Contd..5) 37

Number of Products under Development by Companies, H2 2016 (Contd..6) 38

Number of Products under Development by Companies, H2 2016 (Contd..7) 39

Number of Products under Development by Companies, H2 2016 (Contd..8) 40

Number of Products under Development by Companies, H2 2016 42

Number of Products under Development by Companies, H2 2016 (Contd..1) 43

Number of Products under Development by Companies, H2 2016 (Contd..2) 44

Number of Products under Development by Companies, H2 2016 (Contd..3) 45

Number of Products under Development by Companies, H2 2016 (Contd..4) 46

Number of Products under Development by Companies, H2 2016 (Contd..5) 47

Number of Products under Development by Companies, H2 2016 (Contd..6) 48

Number of Products under Development by Companies, H2 2016 (Contd..7) 49

Number of Products under Development by Companies, H2 2016 (Contd..8) 50

Number of Products under Development by Companies, H2 2016 (Contd..9) 51

Number of Products under Development by Companies, H2 2016 (Contd..10) 52

Number of Products under Development by Companies, H2 2016 (Contd..11) 53

Number of Products under Development by Companies, H2 2016 (Contd..12) 54

Number of Products under Development by Companies, H2 2016 (Contd..13) 55

Number of Products under Development by Companies, H2 2016 (Contd..14) 56

Number of Products under Development by Companies, H2 2016 (Contd..15) 57

Number of Products under Development by Companies, H2 2016 (Contd..16) 58

Number of Products under Development by Companies, H2 2016 (Contd..17) 59

Number of Products under Development by Companies, H2 2016 (Contd..18) 60

Number of Products under Development by Companies, H2 2016 61

Number of Products under Development by Companies, H2 2016 (Contd..1) 62

Number of Products under Development by Companies, H2 2016 (Contd..2) 63

Number of Products under Development by Companies, H2 2016 (Contd..3) 64

Number of Products under Development by Companies, H2 2016 (Contd..4) 65

Number of Products under Development by Companies, H2 2016 (Contd..5) 66

Number of Products under Development by Companies, H2 2016 (Contd..6) 67

Number of Products under Development by Companies, H2 2016 (Contd..7) 68

Number of Products under Development by Companies, H2 2016 (Contd..8) 69

Number of Products under Investigation by Universities/Institutes, H2 2016 70

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 71

Number of Products under Investigation by Universities/Institutes, H2 2016 72

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 73

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 73

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 74

Number of Products under Investigation by Universities/Institutes, H2 2016 76

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 76

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 77

Comparative Analysis by Late Stage Development, H2 2016 78

Comparative Analysis by Clinical Stage Development, H2 2016 79

Comparative Analysis by Early Stage Development, H2 2016 80

Comparative Analysis by Unknown Stage Development, H2 2016 81

Comparative Analysis by Late Stage Development, H2 2016 81

Comparative Analysis by Clinical Stage Development, H2 2016 82

Comparative Analysis by Early Stage Development, H2 2016 83

Comparative Analysis by Unknown Stage Development, H2 2016 84

Comparative Analysis by Late Stage Development, H2 2016 84

Comparative Analysis by Clinical Stage Development, H2 2016 85

Comparative Analysis by Early Stage Development, H2 2016 86

Comparative Analysis by Unknown Stage Development, H2 2016 86

Products under Development by Companies, H2 2016 87

Products under Development by Companies, H2 2016 (Contd..1) 88

Products under Development by Companies, H2 2016 (Contd..2) 89

Products under Development by Companies, H2 2016 (Contd..3) 89

Products under Development by Companies, H2 2016 (Contd..4) 90

Products under Development by Companies, H2 2016 (Contd..5) 91

Products under Development by Companies, H2 2016 (Contd..6) 92

Products under Development by Companies, H2 2016 (Contd..7) 92

Products under Development by Companies, H2 2016 (Contd..8) 93

Products under Development by Companies, H2 2016 (Contd..9) 94

Products under Development by Companies, H2 2016 (Contd..10) 95

Products under Development by Companies, H2 2016 (Contd..11) 96

Products under Development by Companies, H2 2016 (Contd..12) 97

Products under Development by Companies, H2 2016 98

Products under Development by Companies, H2 2016 (Contd..1) 99

Products under Development by Companies, H2 2016 (Contd..2) 99

Products under Development by Companies, H2 2016 (Contd..3) 100

Products under Development by Companies, H2 2016 (Contd..4) 100

Products under Development by Companies, H2 2016 (Contd..5) 101

Products under Development by Companies, H2 2016 (Contd..6) 101

Products under Development by Companies, H2 2016 (Contd..7) 102

Products under Development by Companies, H2 2016 (Contd..8) 102

Products under Development by Companies, H2 2016 (Contd..9) 103

Products under Development by Companies, H2 2016 (Contd..10) 103

Products under Development by Companies, H2 2016 (Contd..11) 104

Products under Development by Companies, H2 2016 (Contd..12) 104

Products under Development by Companies, H2 2016 (Contd..13) 105

Products under Development by Companies, H2 2016 (Contd..14) 105

Products under Development by Companies, H2 2016 (Contd..15) 106

Products under Development by Companies, H2 2016 (Contd..16) 106

Products under Development by Companies, H2 2016 (Contd..17) 107

Products under Development by Companies, H2 2016 (Contd..18) 107

Products under Development by Companies, H2 2016 (Contd..19) 108

Products under Development by Companies, H2 2016 (Contd..20) 108

Products under Development by Companies, H2 2016 (Contd..21) 109

Products under Development by Companies, H2 2016 (Contd..22) 110

Products under Development by Companies, H2 2016 (Contd..23) 111

Products under Development by Companies, H2 2016 (Contd..24) 112

Products under Development by Companies, H2 2016 (Contd..25) 113

Products under Development by Companies, H2 2016 (Contd..26) 114

Products under Development by Companies, H2 2016 (Contd..27) 115

Products under Development by Companies, H2 2016 (Contd..28) 115

Products under Development by Companies, H2 2016 (Contd..29) 116

Products under Development by Companies, H2 2016 (Contd..30) 117

Products under Development by Companies, H2 2016 (Contd..31) 118

Products under Development by Companies, H2 2016 (Contd..32) 119

Products under Development by Companies, H2 2016 (Contd..33) 120

Products under Development by Companies, H2 2016 121

Products under Development by Companies, H2 2016 (Contd..1) 121

Products under Development by Companies, H2 2016 (Contd..2) 122

Products under Development by Companies, H2 2016 (Contd..3) 122

Products under Development by Companies, H2 2016 (Contd..4) 123

Products under Development by Companies, H2 2016 (Contd..5) 123

Products under Development by Companies, H2 2016 (Contd..6) 124

Products under Development by Companies, H2 2016 (Contd..7) 125

Products under Development by Companies, H2 2016 (Contd..8) 126

Products under Development by Companies, H2 2016 (Contd..9) 127

Products under Development by Companies, H2 2016 (Contd..10) 128

Products under Development by Companies, H2 2016 (Contd..11) 129

Products under Investigation by Universities/Institutes, H2 2016 130

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 131

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 132

Products under Investigation by Universities/Institutes, H2 2016 133

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 137

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 138

Products under Investigation by Universities/Institutes, H2 2016 139

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 140

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 141

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 142

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AbGenomics International, Inc., H2 2016 143

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Adocia, H2 2016 143

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AiCuris GmbH and Co KG, H2 2016 144

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Alteogen Inc., H2 2016 144

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 145

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ambrx, Inc., H2 2016 145

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AntriaBio, Inc., H2 2016 146

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Aphios Corporation, H2 2016 146

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by APT Therapeutics, Inc., H2 2016 147

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 147

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Argos Therapeutics, Inc., H2 2016 148

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Artery Therapeutics, Inc., H2 2016 148

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Astellas Pharma Inc., H2 2016 149

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AstraZeneca Plc, H2 2016 149

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Athersys, Inc., H2 2016 150

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Atlantic Bio Sci LLC, H2 2016 150

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Axxam SpA, H2 2016 151

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Beta-Cell NV, H2 2016 151

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biocon Limited, H2 2016 152

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biogenomics Limited, H2 2016 152

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLineRx, Ltd., H2 2016 153

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLingus AG, H2 2016 153

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioTherapeutics Inc., H2 2016 154

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BirchBioMed Inc, H2 2016 154

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 155

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Caladrius Biosciences Inc, H2 2016 155

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 156

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Carlina Technologies SAS, H2 2016 156

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Compugen Ltd., H2 2016 157

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ConjuChem, LLC, H2 2016 157

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 158

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dance Biopharm Inc., H2 2016 158

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diabetology (Products) Ltd, H2 2016 159

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by DiaMedica Inc., H2 2016 159

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diamyd Medical AB, H2 2016 160

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diasome Pharmaceuticals, Inc., H2 2016 160

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 161

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Eli Lilly and Company, H2 2016 161

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by enGene, Inc, H2 2016 162

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ensol Biosciences Inc., H2 2016 162

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by EpiVax, Inc., H2 2016 162

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Escape Therapeutics, Inc., H2 2016 163

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Evotec AG, H2 2016 163

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 164

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Fate Therapeutics, Inc., H2 2016 164

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Generex Biotechnology Corporation, H2 2016 165

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GeNeuro SA, H2 2016 165

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Geropharm, H2 2016 166

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Gilead Sciences, Inc., H2 2016 166

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GlaxoSmithKline Plc, H2 2016 167

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Grifols, S.A., H2 2016 167

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Heptares Therapeutics Limited, H2 2016 168

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Iltoo Pharma, H2 2016 168

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ImmusanT, Inc., H2 2016 168

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Innopharmax Inc., H2 2016 169

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Intrexon Corporation, H2 2016 169

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Islet Sciences, Inc., H2 2016 170

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Johnson & Johnson, H2 2016 170

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kadimastem Ltd., H2 2016 171

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kamada Ltd., H2 2016 171

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kasiak Research Private Limited, H2 2016 172

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by KPI Therapeutics, Inc., H2 2016 172

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 173

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 173

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Lonestar Heart, Inc., H2 2016 174

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MacroGenics, Inc., H2 2016 174

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medestea Research & Production S.p.A., H2 2016 175

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MedImmune LLC, H2 2016 175

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medy-Tox Inc., H2 2016 176

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Merck & Co., Inc., H2 2016 176

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Meridigen Biotech Co., Ltd., H2 2016 177

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MidaSol Therapeutics LP, H2 2016 177

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 178

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Novo Nordisk A/S, H2 2016 179

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Noxxon Pharma AG, H2 2016 180

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Oramed Pharmaceuticals, Inc., H2 2016 180

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Orgenesis Inc, H2 2016 181

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by OSE Immunotherapeutics, H2 2016 181

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 182

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Parvus Therapeutics, Inc., H2 2016 182

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pathfinder Cell Therapy Inc, H2 2016 183

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pfizer Inc., H2 2016 183

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaCyte Biotech, Inc., H2 2016 184

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaIN Corporation, H2 2016 184

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Prometheon Pharma, LLC, H2 2016 185

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016 185

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by RedHill Biopharma Ltd., H2 2016 186

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by REGiMMUNE Corporation, H2 2016 186

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sanofi, H2 2016 187

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by SEKRIS Biomedical, Inc., H2 2016 187

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Selecta Biosciences, Inc., H2 2016 188

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Semma Therapeutics Inc., H2 2016 188

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sevion Therapeutics, Inc., H2 2016 189

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Strongbridge Biopharma plc , H2 2016 189

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Therapix Biosciences Ltd., H2 2016 190

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Thermalin Diabetes, LLC, H2 2016 190

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Toleranzia AB, H2 2016 191

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Transgene Biotek Limited, H2 2016 191

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by UCB SA, H2 2016 192

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Unicyte AG, H2 2016 192

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by United Therapeutics Corporation, H2 2016 193

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ViaCyte, Inc., H2 2016 193

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Visionary Pharmaceuticals, Inc., H2 2016 194

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XL-protein GmbH, H2 2016 194

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XOMA Corporation, H2 2016 195

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 195

Type 2 Diabetes – Pipeline by Addex Therapeutics Ltd, H2 2016 196

Type 2 Diabetes – Pipeline by Adocia, H2 2016 196

Type 2 Diabetes – Pipeline by Advinus Therapeutics Ltd, H2 2016 197

Type 2 Diabetes – Pipeline by Aegis Therapeutics, LLC, H2 2016 197

Type 2 Diabetes – Pipeline by AFFiRiS AG, H2 2016 198

Type 2 Diabetes – Pipeline by Alize Pharma SAS, H2 2016 198

List Of Figures, Charts and Diagrams
in Diabetes & Obesity Drug Development Pipeline Review, 2016

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 25

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 26

Number of Products under Development for Type 2 Diabetes, H2 2016 27

Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 28

Number of Products under Development for Obesity, H2 2016 29

Number of Products under Development for Obesity – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Development by Companies, H2 2016 41

Number of Products under Development by Companies, H2 2016 61

Number of Products under Investigation by Universities/Institutes, H2 2016 70

Number of Products under Investigation by Universities/Institutes, H2 2016 72

Number of Products under Investigation by Universities/Institutes, H2 2016 75

Comparative Analysis by Late Stage Development, H2 2016 78

Comparative Analysis by Clinical Stage Development, H2 2016 79

Comparative Analysis by Early Stage Products, H2 2016 80

Comparative Analysis by Late Stage Development, H2 2016 81

Comparative Analysis by Clinical Stage Development, H2 2016 82

Comparative Analysis by Early Stage Products, H2 2016 83

Comparative Analysis by Late Stage Development, H2 2016 84

Comparative Analysis by Clinical Stage Development, H2 2016 85

Comparative Analysis by Early Stage Products, H2 2016 86

Assessment by Monotherapy Products, H2 2016 361

Assessment by Combination Products, H2 2016 362

Number of Products by Top 10 Targets, H2 2016 363

Number of Products by Stage and Top 10 Targets, H2 2016 363

Number of Products by Top 10 Mechanism of Actions, H2 2016 373

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 373

Number of Products by Top 10 Routes of Administration, H2 2016 383

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 383

Number of Products by Top 10 Molecule Types, H2 2016 385

Number of Products by Stage and Top 10 Molecule Types, H2 2016 385

Assessment by Monotherapy Products, H2 2016 387

Assessment by Combination Products, H2 2016 388

Number of Products by Top 10 Targets, H2 2016 389

Number of Products by Stage and Top 10 Targets, H2 2016 389

Number of Products by Top 10 Mechanism of Actions, H2 2016 410

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 410

Number of Products by Top 10 Routes of Administration, H2 2016 436

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 436

Number of Products by Top 10 Molecule Types, H2 2016 438

Number of Products by Stage and Top 10 Molecule Types, H2 2016 438

Assessment by Monotherapy Products, H2 2016 440

Assessment by Combination Products, H2 2016 441

Number of Products by Top 10 Targets, H2 2016 442

Number of Products by Stage and Top 10 Targets, H2 2016 442

Number of Products by Top 10 Mechanism of Actions, H2 2016 450

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 450

Number of Products by Routes of Administration, H2 2016 458

Number of Products by Stage and Routes of Administration, H2 2016 458

Number of Products by Top 10 Molecule Types, H2 2016 460

Number of Products by Stage and Top 10 Molecule Types, H2 2016 460

Additional Details

Publisher

GBI Research

Publisher Information

Reference

25791 |

Number of Pages

560

Report Format

PDF

GBI Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US)
IntroductionWhat environmental market barriers are influencing the Type 2 Diabetes (T2DM) market? F...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5)
IntroductionWhat market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to a...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
Physician Views: How do endocrinologists value diabetes-focused medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
08 Dec 2014 by FirstWord Pharma USD $695 More Info
Physician Views: US formulary management in diabetes – are endocrinologists impressed?
Scope Pricing pressure exerted by US pharmacy benefit managers (PBMs) and managed care organisations...
12 Aug 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Five key diabetes market questions ahead of ADA 2014
Scope This year's annual meeting of the American Diabetes Association (ADA) – which will take place ...
13 Jun 2014 by FirstWord Pharma USD $695 More Info
Diabetes -- KOL Insight and Consensus Outlook Modules
IntroductionThe medium term: battle lines are drawnThe fundamental drivers of the global diabetes ma...
01 May 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
01 Aug 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Post ADA view on key diabetes market developments
ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
01 Jul 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
01 Jul 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
01 Jun 2013 by FirstWord Pharma USD $695 More Info

This report is published by GBI Research

Download Free Report Summary PDF

Diabetes & Obesity Drug Development Pipeline Review, 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data